Advertisement

Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab

      Background: Altered tissue remodeling and collagen turnover in the tumor microenvironment can affect drug delivery as well as T-cell infiltration and activity and hereby affect response to immune checkpoint inhibitors. The aim of this study was to evaluate the association between serum biomarkers of type III collagen formation and degradation and outcome in metastatic melanoma patients treated with Ipilimumab (Ipi).
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect